🟢 Inovio Pharmaceuticals is trading 6.7% up in pre-market with no clear catalyst identified

Inovio Pharmaceuticals is trading at $1.11, up 6.7% in pre-market, with no clear company-specific catalyst identified for the October 16 rise.

• Recent news reported AstraZeneca reduced its collaboration with Inovio to one vaccine, while retaining milestone and royalty potential for MEDI0457.
• That report described an earlier pre-market drop, not a reason for this gain.
• Broader index futures were mixed, with no major same-direction market move evident in the supplied context.